Steward Partners Investment Advisory LLC Has $44,000 Holdings in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)

Steward Partners Investment Advisory LLC cut its stake in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRMGet Rating) by 60.0% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,000 shares of the company’s stock after selling 3,000 shares during the period. Steward Partners Investment Advisory LLC’s holdings in Mirum Pharmaceuticals were worth $44,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Russell Investments Group Ltd. acquired a new stake in Mirum Pharmaceuticals during the 4th quarter valued at $606,000. Integral Health Asset Management LLC acquired a new stake in Mirum Pharmaceuticals during the 4th quarter valued at $1,595,000. Congress Wealth Management LLC DE acquired a new stake in Mirum Pharmaceuticals during the 4th quarter valued at $160,000. Raymond James Financial Services Advisors Inc. increased its holdings in Mirum Pharmaceuticals by 6.6% during the 4th quarter. Raymond James Financial Services Advisors Inc. now owns 25,322 shares of the company’s stock valued at $404,000 after purchasing an additional 1,574 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. acquired a new stake in Mirum Pharmaceuticals during the 4th quarter valued at $409,000. 87.68% of the stock is owned by institutional investors and hedge funds.

Mirum Pharmaceuticals Stock Up 11.8 %

NASDAQ:MIRM opened at $26.05 on Friday. Mirum Pharmaceuticals, Inc. has a 12-month low of $12.82 and a 12-month high of $28.65. The firm has a market capitalization of $829.30 million, a P/E ratio of -11.53 and a beta of 1.44. The stock’s fifty day simple moving average is $22.48 and its 200-day simple moving average is $22.69.

Mirum Pharmaceuticals (NASDAQ:MIRMGet Rating) last posted its quarterly earnings results on Thursday, May 5th. The company reported ($1.17) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.39) by $0.22. The business had revenue of $12.89 million for the quarter, compared to analyst estimates of $8.68 million. Mirum Pharmaceuticals had a negative return on equity of 163.01% and a negative net margin of 218.74%. During the same period last year, the company earned ($1.68) EPS. As a group, equities research analysts expect that Mirum Pharmaceuticals, Inc. will post -4.35 earnings per share for the current year.

Wall Street Analyst Weigh In

MIRM has been the subject of a number of recent analyst reports. SVB Leerink raised their price target on Mirum Pharmaceuticals from $50.00 to $52.00 and gave the company an “outperform” rating in a report on Tuesday, May 24th. HC Wainwright lifted their target price on Mirum Pharmaceuticals from $64.00 to $69.00 and gave the company a “buy” rating in a research note on Monday, May 23rd. Four equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $51.80.

Insiders Place Their Bets

In other Mirum Pharmaceuticals news, major shareholder James E. Flynn sold 38,478 shares of Mirum Pharmaceuticals stock in a transaction dated Monday, June 6th. The stock was sold at an average price of $25.01, for a total transaction of $962,334.78. Following the transaction, the insider now directly owns 1,540,190 shares in the company, valued at $38,520,151.90. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 33.27% of the company’s stock.

Mirum Pharmaceuticals Company Profile

(Get Rating)

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease.

Featured Articles

Want to see what other hedge funds are holding MIRM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mirum Pharmaceuticals, Inc. (NASDAQ:MIRMGet Rating).

Institutional Ownership by Quarter for Mirum Pharmaceuticals (NASDAQ:MIRM)

Want More Great Investing Ideas?

Receive News & Ratings for Mirum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.